November 27, 2018 10:29 AM ESTUpdated 12:18 PM

BeiGene inks $60M licensing, research pacts with Zymeworks; Merck, AbbVie, Amgen back neuro upstart

ENDPOINTS

→ The savvy dealmakers at Zymeworks $ZYME have scored another heavyweight partner as BeiGene signs on for regional rights to two of its early-stage assets …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BeiGene inks $60M licensing, research pacts with Zymeworks; Merck, AbbVie, Amgen back neuro upstart

ENDPOINTS

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

Teva launches Stelara biosimilar at 85% discount as wider field emerges

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

BeiGene inks $60M li­cens­ing, re­search pacts with Zymeworks; Mer­ck, Ab­b­Vie, Am­gen back neu­ro up­start

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

BeiGene inks $60M licensing, research pacts with Zymeworks; Merck, AbbVie, Amgen back neuro upstart